바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

2오늘 방문

554누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

ADCCHotBiologicGlaxoSmithKlinePreclinical

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

HIV Infections; Hepatitis B · HIV Infections

#HIVInfections#ADC#Preclinical#인기#항체약물접합체+3

효능 ORR 94.99%임상시험 121상태 ACTIVE

ADCCHotBiologicGileadderuxtecan, sacituzumab gov…Phase 2

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

Urothelial Carcinoma; Muscle-invasive Bladder Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 44%임상시험 121상태 RECRUITING

AntibodyCHotAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#인기#항체+5

효능 ORR 37.4%임상시험 118상태 RECRUITING

ADCAHotBiologicGenentech, Inc.Approved

Methylprednisolone (Methylprednisolone)

Rheumatoid Arthritis · Ann Arbor Stage IIB Hodgkin Lymphoma

#AnnArborStageIIBHodgkinLymphoma#ADC#Approved#인기#항체약물접합체+3

효능 ORR 88%임상시험 118상태 RECRUITING

ADCBHotBiologicSeagenPreclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#인기#항체약물접합체+3

효능 ORR 89.5%임상시험 118상태 ACTIVE

AntibodySHOTFDACuratedFDABiologicAmgenApproved

etanercept (Enbrel, Erelzi)

RA, psoriasis, psoriatic arthritis, ankylosing spondylitis · TNF

#TNF#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 73.4%임상시험 117상태 APPROVED

ADCBHotBiologicAstellasvedotin plus pembrolizumab …Phase 3

EV (enfortumab vedotin, enfortumab vedotin (EV))

Urothelial Carcinoma (UC); Peripheral Nerve Disease · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 44%임상시험 117상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicJanssenApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 75%임상시험 116상태 APPROVED

AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5

효능 ORR 95%임상시험 115상태 RECRUITING

ADCCHotBiologicAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#인기#항체약물접합체+3

효능 ORR 31.2%임상시험 114상태 RECRUITING

AntibodyBHotRochePhase 3

R (Rituximab, Rituximab (R))

Primary Central Nervous System Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase3#인기#항체+4

효능 ORR 95%임상시험 114상태 ACTIVE

AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5

효능 ORR 100%임상시험 114상태 RECRUITING

AntibodyBHotBiologicRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5

효능 ORR 91.2%임상시험 113상태 RECRUITING

CGTCHotBiologicThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5

효능 ORR 97.1%임상시험 113상태 DISCONTINUED

ADCAHotBiologicUlrik LassenPhase 2

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

Cancer; Tumors · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 67.6%임상시험 112상태 RECRUITING

AntibodyAHotMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5

효능 ORR 93.5%임상시험 111상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 66.4%임상시험 110상태 APPROVED

ADCBHotBiologicFBD Biologics LimitedPhase 2

AUC 5 (Carboplatin, Carboplatin (AUC 5))

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 84%임상시험 110상태 RECRUITING

AntibodyBHotMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3

효능 ORR 56.1%임상시험 110상태 ACTIVE

ADCCHotBiologicSCRI Development Innovations, L…Phase 3

everolimus (everolimus)

Intracranial Meningioma · Renal Cell Carcinoma

#RenalCellCarcinoma#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 78.4%임상시험 109상태 DISCONTINUED

ADCBHotBiologicRochePhase 2

Liquid (Polatuzumab vedotin, Polatuzumab vedotin (Liquid))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 100%임상시험 109상태 ACTIVE

ADCBHotBiologicRochePhase 2

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 100%임상시험 108상태 ACTIVE

ADCBHotBiologicDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2

효능 ORR 69.7%임상시험 107상태 ACTIVE

ADCCHotBiologicRochePhase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 100%임상시험 106상태 DISCONTINUED

ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5

효능 ORR 69.7%임상시험 106상태 RECRUITING

3 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 2 / 554

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Methylprednisolone (Methylprednisolone)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

etanercept (Enbrel, Erelzi)

EV (enfortumab vedotin, enfortumab vedotin (EV))

ustekinumab (Stelara, Wezlana)

Tocilizumab (Tocilizumab)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

R (Rituximab, Rituximab (R))

Obinutuzumab (Obinutuzumab)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

AUC 5 (Carboplatin, Carboplatin (AUC 5))

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

everolimus (everolimus)

Liquid (Polatuzumab vedotin, Polatuzumab vedotin (Liquid))

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

DP (DS-8201a, DS-8201a (DP))

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

trastuzumab (Herceptin, Trastuzumab Emtansine)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Methylprednisolone (Methylprednisolone)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

etanercept (Enbrel, Erelzi)

EV (enfortumab vedotin, enfortumab vedotin (EV))

ustekinumab (Stelara, Wezlana)

Tocilizumab (Tocilizumab)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

R (Rituximab, Rituximab (R))

Obinutuzumab (Obinutuzumab)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

AUC 5 (Carboplatin, Carboplatin (AUC 5))

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

everolimus (everolimus)

Liquid (Polatuzumab vedotin, Polatuzumab vedotin (Liquid))

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

DP (DS-8201a, DS-8201a (DP))

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

trastuzumab (Herceptin, Trastuzumab Emtansine)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Methylprednisolone (Methylprednisolone)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

etanercept (Enbrel, Erelzi)

EV (enfortumab vedotin, enfortumab vedotin (EV))

ustekinumab (Stelara, Wezlana)

Tocilizumab (Tocilizumab)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

R (Rituximab, Rituximab (R))

Obinutuzumab (Obinutuzumab)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))